Outcomes for early-relapsing patients with other small molecules
| Drug . | ORR (overall) . | ORR (POD24) . | CR (Overall) . | CR (POD24) . | PFS (Overall) . | PFS (POD24) . | OS . |
|---|---|---|---|---|---|---|---|
| Tazemetostat39,40 | |||||||
| MT pop. | 69% | 63% | 13% | N/A | 13.8 mo | 13.8 mo | N/A |
| WT pop. | 35% | 25% | 4% | N/A | 11.1 mo | 5.8 mo | N/A |
| Idelalisib32,36 | 57% | 56.8% | 6% | 13.5% | 11 mo | 11.1 mo | N/A |
| Copanlisib33 | 58.7% | 60.3% | 20.2% | 22.1% | 12.5 mo* | 11.3 mo | |
| Duvelisib34 | 42.2% | 33% | 1.2% | 9.5 mo | 8.2 mo | 77% at 1 y* | |
| Umbralisib35 | 45.3% | N/A | 5.1% | N/A | 10.6 mo | N/A | N/A |
| Zandelisib37 | 77.8% 94.7% | 81.8% | 27.8% 26.3% | 18.2% | N/A | N/A | N/A |
| Drug . | ORR (overall) . | ORR (POD24) . | CR (Overall) . | CR (POD24) . | PFS (Overall) . | PFS (POD24) . | OS . |
|---|---|---|---|---|---|---|---|
| Tazemetostat39,40 | |||||||
| MT pop. | 69% | 63% | 13% | N/A | 13.8 mo | 13.8 mo | N/A |
| WT pop. | 35% | 25% | 4% | N/A | 11.1 mo | 5.8 mo | N/A |
| Idelalisib32,36 | 57% | 56.8% | 6% | 13.5% | 11 mo | 11.1 mo | N/A |
| Copanlisib33 | 58.7% | 60.3% | 20.2% | 22.1% | 12.5 mo* | 11.3 mo | |
| Duvelisib34 | 42.2% | 33% | 1.2% | 9.5 mo | 8.2 mo | 77% at 1 y* | |
| Umbralisib35 | 45.3% | N/A | 5.1% | N/A | 10.6 mo | N/A | N/A |
| Zandelisib37 | 77.8% 94.7% | 81.8% | 27.8% 26.3% | 18.2% | N/A | N/A | N/A |
All subtypes.
N/A, not available.